Precigen, Inc. (NASDAQ:PGEN)’s share price fell 5.4% during trading on Tuesday . The company traded as low as $7.24 and last traded at $7.24. 9,914 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 1,779,671 shares. The stock had previously closed at $7.65.

PGEN has been the subject of a number of analyst reports. Wells Fargo & Company started coverage on shares of Precigen in a research note on Monday, March 1st. They set an “overweight” rating and a $14.00 target price for the company. Zacks Investment Research lowered shares of Precigen from a “hold” rating to a “sell” rating in a report on Friday, March 5th. B. Riley increased their price objective on shares of Precigen from $10.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, March 2nd. Stifel Nicolaus began coverage on Precigen in a research note on Wednesday, March 3rd. They set a “buy” rating and a $13.00 price target on the stock. Finally, HC Wainwright increased their price target on Precigen from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Wednesday, December 16th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Precigen currently has a consensus rating of “Buy” and an average target price of $11.54.

The company has a debt-to-equity ratio of 3.31, a quick ratio of 4.59 and a current ratio of 4.93. The business has a 50 day simple moving average of $8.08 and a 200-day simple moving average of $7.29. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of -3.61 and a beta of 2.31.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Sunday, February 28th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.06). The company had revenue of $19.33 million for the quarter, compared to the consensus estimate of $23.05 million. Precigen had a negative return on equity of 150.85% and a negative net margin of 295.57%. As a group, research analysts anticipate that Precigen, Inc. will post -0.47 earnings per share for the current year.

Several hedge funds have recently made changes to their positions in PGEN. Pacer Advisors Inc. bought a new position in shares of Precigen during the fourth quarter valued at about $36,000. Baron Silver Stevens Financial Advisors LLC purchased a new stake in Precigen in the 4th quarter valued at about $38,000. Penserra Capital Management LLC lifted its position in shares of Precigen by 189.1% during the 4th quarter. Penserra Capital Management LLC now owns 4,255 shares of the biotechnology company’s stock worth $43,000 after buying an additional 2,783 shares in the last quarter. Truvestments Capital LLC purchased a new position in shares of Precigen in the 4th quarter worth approximately $44,000. Finally, Inspire Advisors LLC bought a new position in shares of Precigen in the fourth quarter valued at approximately $46,000. Institutional investors own 66.57% of the company’s stock.

About Precigen (NASDAQ:PGEN)

Precigen, Inc discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies.

See Also: Do Tariffs Work?

Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.